Pulmonology Perspectives on Biomarker Testing in NSCLC: Multidisciplinary Management in an Era of Rapid Change
This dynamic live symposium, led by top experts in the field of pulmonary medicine and NSCLC, will take attendees on a deep dive into the sentinel role of the pulmonologist in the NSCLC management paradigm, exploring adaptive mechanisms to optimize collaborative strategies in a patient centric manner.
Pulmonologists, medical oncologists, pathologists, oncology APPs (APRNs and PAs), and pharmacists.
- Review the sentinel placement of the pulmonologist in the management of NSCLC, including their principal role in diagnostics, disease staging, and molecular testing.
- Evaluate clinical and patient-value driven factors that may help inform nodule evaluation and diagnostic strategies for pulmonologists, thus ensuring “the right tissue in the right amount from the right place for the right patient.”
- Demonstrate knowledge of guideline recommendations and practical considerations for the use of EBUS-TBNA techniques by pulmonologists, emphasizing the fundamentals of safely and effectively obtaining adequate tissue for diagnosis and molecular characterization.
- Describe the evolving role of targeted therapy and immunotherapy in NSCLC and analyze currently FDA-approved therapeutics across the NSCLC disease continuum, highlighting the role of molecular testing for guiding treatment and individualizing patient care.
- Explore the established utility of next-generation sequencing (NGS) and discuss the potential for emerging “next-generation” biomarkers in the NSCLC management paradigm.
- Apply patient-centric, evidence-supported collaborative care strategies to real-world, case-based scenarios in order to elucidate the pivotal role of the pulmonologist on the multidisciplinary team across the NSCLC continuum of care.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
5 min: Welcome and Introductions, Pre-test
- NSCLC epidemiology and the close tie between prompt diagnostic staging and survival
- Advancements in NSCLC disease management that have altered prognostic outcomes, including the foundational impact of molecular characterization and the role diagnostics in guiding and informing targeted therapeutic strategies
- The established role of the pulmonologist along all phases of care, particularly in the initial disease diagnosis, staging, and risk stratification
- Indications for invasive staging techniques, particularly focused on EBUS-TBNA with or without ROSE and strategies to optimize this process for optimal tissue acquisition
- Guideline recommendations and current consensus on practical EBUS considerations, including number of passes needed for diagnosis as well as additional sampling needed for conductance of necessary molecular testing
- Established “druggable” driver mutations, rearrangements, and key biomarkers in the therapeutic landscape
- Guideline-directed testing algorithms and considerations for optimizing tissue samples to obtain the most precise diagnosis to guide treatment
- Recent clinical trial readouts establishing the role of immunotherapy and targeted therapeutics across the totality of the NSCLC disease spectrum (both early-stage, stage III, and advanced)
- Future expectations for targeted therapy in NSCLC and an evaluation of next-generation biomarkers, focusing on the potential for practice-changing implications beyond current standards
- Case-based discussions among the multidisciplinary team, highlighting the prominent, real-world role of the pulmonologist in NSCLC diagnostics
- Practical scenarios demonstrating techniques to improve tissue sampling for optimal yield and accurate diagnosis, staging, molecular testing, and initiation of appropriate, evidence-supported treatment protocols
20 min: Audience Q&A, Post-test
Gerard A. Silvestri, MD, MS (Activity chair)
George C. and Margaret M. Hillenbrand Endowed Chair
Professor, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine
Medical University of South Carolina
Jill Feldman, MA
Lung Cancer Patient and Advocate
Chair, IASLC Patient Advocacy Committee
Co-Founder EGFR Resisters
Deerfield Park, IL
Hiren Mehta, MD
Professor of Medicine
Medical Director, UF Shands Medical Intensive Care Unit
Division Vice-Chief for Medical Affairs
Program Director, Interventional Pulmonology Fellowship Program
University of Florida Health
Raymond U. Osarogiagbon, MD
Director, Multidisciplinary Thoracic Oncology Program
Baptist Cancer Center
Lynette M. Sholl, MD
Associate Professor, Pathology
Harvard Medical School
Brigham and Women's Hospital
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Kevin Ma, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jill Feldman, MA–has disclosed that she is an advisor or consultant to Blueprint Medicine, Daiichi-Sankyo, EQRx, and Janssen. She also receives other financial or material support from AstraZeneca, Blueprint Medicine, and Takeda.
Hiren Mehta, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Raymond U. Osarogiagbon, MD–has disclosed that he is an advisor or consultant to AstraZeneca and Genentech. He also owns stock or is a shareholder in Eil Lilly, Gilead Sciences, and Pfizer.
Lynette M. Sholl, MD–has disclosed that she receives grants from Bristol Myers Squibb and Genentech. She is also an advisor or consultant to AstraZeneca, Eli Lilly, Genentech, and GV20 Therapeutics.
Gerard A. Silvestri, MD, MS–has disclosed that he receives research support from Amgen, Auris, Biodesix, Delfi, Exact Sciences, NCI, Nucleix, Olympus, PCORI, and SEER Inc. He is an advisor or consultant for Biodesix and Olympus.
Adam Fox, MD–has disclosed that he receives an Internal NIH grant: K12-CA157688, research support from the American Cancer Society and Olympus and is on the speakers bureau for the Association of Community Cancer Centers. He also owns self managed stock/shareholder of Merck.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Participation